Extended Data Table 1 Study treatment discontinuation

From: Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

  1. Values are number of patients, n (%). Population is all treated patients. Primary and expansion cohorts.
  2. aPatients may have only one primary reason for discontinuation.
  3. G, grade.
Back to article page